Oncternal Therapeutics, Inc. (ONCT)

Oncternal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Quarter Ending	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Cash & Equivalents	13.08	6.38	6.4	6.7	14.93	15.83	11.24	37.14	70.63	78.9	82.16	90.77	97.38	103.66	111.21	116.74	21.26	16.62	16.02	20.05
Short-Term Investments	1.5	15.05	20.63	27.56	25.38	29.67	43.07	26.58	0	0	0	0	0	0	0	0	0	0	0	0
Cash & Cash Equivalents	14.58	21.43	27.03	34.26	40.31	45.5	54.32	63.72	70.63	78.9	82.16	90.77	97.38	103.66	111.21	116.74	21.26	16.62	16.02	20.05
Cash Growth	-63.83%	-52.91%	-50.24%	-46.24%	-42.93%	-42.33%	-33.89%	-29.79%	-27.47%	-23.89%	-26.12%	-22.25%	358.06%	523.84%	594.24%	482.20%	-7.95%	-41.73%	-24.39%	-2.88%
Other Current Assets	0.87	1.83	1.48	1.8	2.19	4.57	3.6	3.57	4.16	2.08	2.91	2.09	2.14	3.94	1.87	1.27	1.45	1.4	0.55	0.74
Total Current Assets	15.45	23.26	28.5	36.06	42.49	50.08	57.92	67.29	74.79	80.98	85.07	92.85	99.52	107.6	113.08	118	22.71	18.02	16.56	20.79
Property, Plant & Equipment	0.15	0.19	0.23	0.26	0.29	0.37	0.05	0.09	0.12	0.16	0.03	0.08	0.12	0.16	0.2	0.04	0.08	0.12	0.15	0.19
Other Long-Term Assets	0	0.41	0.41	0.41	0.41	0.33	0.32	1.27	1.26	0.39	0.39	0.66	0.66	0.66	0.77	0.77	0.77	0.77	1.05	0.77
Total Long-Term Assets	0.15	0.6	0.64	0.67	0.7	0.7	0.37	1.36	1.38	0.55	0.42	0.73	0.78	0.82	0.97	0.81	0.85	0.88	1.2	0.96
Total Assets	15.6	23.86	29.14	36.73	43.2	50.77	58.28	68.65	76.17	81.53	85.49	93.59	100.3	108.42	114.06	118.81	23.55	18.9	17.77	21.74
Accounts Payable	1.2	1.9	1.46	1.15	2.13	2.22	1.96	2.92	2.46	2.52	2.4	1.96	2.75	1.01	1.89	1.14	0.98	1.47	1.38	0.87
Deferred Revenue	0	0	0	0	0	0	0	0	0.12	0.21	0	0	0.16	2.24	0.89	1.63	3.22	3.81	3.06	3.64
Current Debt	0.19	0.19	0.18	0.17	0.15	0.15	0.05	0.09	0.12	0.14	0.03	0.08	0.12	0.16	0.17	0.04	0.08	0.12	0.1	0.1
Other Current Liabilities	5.06	5.97	4.48	3.88	2.87	2.46	3.47	4.68	4.93	4.64	2.87	3.43	2.8	2.49	2.77	3.04	3.27	3.61	2.78	2.73
Total Current Liabilities	6.45	8.06	6.12	5.2	5.15	4.83	5.49	7.68	7.63	7.51	5.29	5.47	5.82	5.9	5.72	5.86	7.55	9	7.32	7.34
Long-Term Debt	0	0.05	0.1	0.15	0.19	0.22	0	0	0	0.01	0	0	0	0	0.03	0	0.3	0.3	0.05	0.09
Other Long-Term Liabilities	0	0	0	1.33	0.86	0.54	0.31	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Long-Term Liabilities	0	0.05	0.1	1.48	1.05	0.76	0.31	0	0	0.01	0	0	0	0	0.03	0	0.3	0.3	0.05	0.09
Total Liabilities	6.45	8.11	6.22	6.68	6.2	5.59	5.79	7.68	7.63	7.53	5.29	5.47	5.82	5.9	5.75	5.86	7.85	9.3	7.37	7.43
Total Debt	0.19	0.24	0.28	0.32	0.34	0.37	0.05	0.09	0.12	0.16	0.03	0.08	0.12	0.16	0.2	0.04	0.38	0.42	0.15	0.19
Debt Growth	-44.15%	-35.79%	456.00%	265.52%	180.33%	133.12%	61.29%	16.00%	2.52%	-3.09%	-84.80%	87.50%	-68.68%	-61.24%	32.47%	-78.95%	68.89%	57.74%	-	-
Retained Earnings	-223.19	-214.73	-206.17	-197.78	-188.62	-178.75	-169.79	-158.3	-146.9	-135.78	-124.03	-114.13	-106.06	-96.43	-88.75	-82.8	-80.24	-75.85	-70.31	-65.57
Comprehensive Income	0	-0	-0.01	0	0	-0.01	0.01	0.01	0	0	0	0	0	0	0	0	0	0	0	0
Shareholders' Equity	9.15	15.75	22.93	30.05	37	45.18	52.49	60.97	68.54	74	80.19	88.12	94.48	102.52	108.3	112.95	15.7	9.6	10.4	14.31
Net Cash (Debt)	14.39	21.19	26.75	33.94	39.96	45.14	54.27	63.64	70.51	78.74	82.13	90.69	97.26	103.5	111.01	116.7	20.88	16.2	15.87	19.86
Net Cash (Debt) Growth	-64.00%	-53.05%	-50.71%	-46.67%	-43.32%	-42.68%	-33.92%	-29.83%	-27.51%	-23.92%	-26.02%	-22.29%	365.83%	538.93%	599.70%	487.57%	-8.71%	-42.66%	-25.12%	-3.80%
Net Cash Per Share	4.86	7.16	9.04	11.51	13.56	15.37	18.55	22.47	26.01	31.46	33.23	36.70	39.38	41.93	45.22	114.94	20.75	19.95	20.66	38.46
Working Capital	8.99	15.2	22.39	30.86	37.34	45.24	52.43	59.61	67.16	73.47	79.77	87.39	93.7	101.7	107.36	112.15	15.16	9.02	9.25	13.45
Book Value Per Share	3.09	5.32	7.75	10.19	12.55	15.39	17.94	21.53	25.29	29.56	32.45	35.66	38.26	41.54	44.12	111.25	15.60	11.82	13.54	27.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).